Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002320 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT00002320 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 320 participants.
The verdict
NCT00002320, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002320
The ClinicalTrials.gov registry entry for NCT00002320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002320 about?
NCT00002320 is a clinical study titled "A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past". To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.
What is the current status of trial NCT00002320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants.
What interventions are being tested in trial NCT00002320?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00002320?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.